Compare Advance Auto Parts, Inc. (AAP) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Advance Auto Parts, Inc. vs Merck & Co., Inc. — how do they compare? Advance Auto Parts, Inc. trades at $55.05 (market cap $3.37B), while Merck & Co., Inc. trades at $126.87 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 94.4× Advance Auto Parts, Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| AAP | MRK | |
|---|---|---|
Market Cap | $3.37B | $318.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $66.50 | $129.52 |
52-Week Low | $38.75 | $77.60 |
Enterprise Value | $5.64B | $361.68B |
Dividend Yield | 1.79% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Advance Auto Parts (AAP) trades at $55.86, down 9.22% today, reflecting recent pressure despite beating earnings estimates in three consecutive quarters. The stock shows a bearish technical signal with key support at $55 and resistance at $59. Fundamentally, revenue has declined from $11.2B in 2022 to $8.6B in 2025, though net income turned positive at $44M in 2025 after a loss in 2024. Recent news highlights a brand campaign and expanded delivery partnership with OneRail.
The outlook is mixed; analyst consensus is a Hold with a $60.89 price target, suggesting modest upside. Opportunities include margin expansion and turnaround progress, but risks involve competitive pressures, volatile cash flows, and high P/E ratio. Investor sentiment is cautious amid declining revenue trends.
Merck (MRK) trades at $126.07, down 0.56% on the day, with a bullish technical signal and strong institutional interest. Recent earnings beats and a 67.57% analyst buy rating reflect confidence, while the acquisition of Terns Pharmaceuticals bolsters its oncology pipeline. The stock shows robust profitability with a net income margin of 28.07% in 2025, though valuation multiples like a P/E of 36.3 suggest premium pricing.
The outlook remains positive with a consensus price target of $139.33, offering potential upside. Key risks include integration challenges from acquisitions and patent expirations. Revenue growth is steady, but investors should monitor debt levels, which rose to 36.06% of assets in 2025, and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Advance Auto Parts, Inc.
Advance Auto Parts is one of the industry's largest retailers of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in North America. Advance operated 4,972 stores as of the end of 2021, in addition to servicing 1,317 independently owned Carquest stores. The company's Worldpac unit is a premier distributor of imported original-equipment parts. Advance derived 58% of its 2021 sales from commercial clients, up from 30%-40% before the General Parts deal.
Read more on AAP →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
